Clinical effects of cigarette smoking: Epidemiologic impact and review of pharmacotherapy options

International Journal of Environmental Research and Public Health

Volumn 14, Issue 10, 2017, Pages

  Onor, IfeanyiChukwu O ^a,b   Stirling, Daniel L ^a   Williams, Shandrika R ^a   Bediako, Daniel ^a   Borghol, Amne ^a,b   Harris, Martha B ^a   Darensburg, Tiernisha B ^a   Clay, Sharde D ^a   Okpechi, Samuel C ^b   Sarpong, Daniel F ^a  

^a Xavier University of Louisiana College of Pharmacy   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse health effects; Cigarette; Non pharmacologic therapy; Pharmacotherapy; Smoking; Tobacco

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NORTRIPTYLINE; VARENICLINE;

EPIDEMIOLOGY; HEALTH CARE; HEALTH IMPACT; LITERATURE REVIEW; PUBLIC HEALTH; RISK FACTOR; SMOKE; SMOKING; TOBACCO;

ACUPUNCTURE; AORTIC ANEURYSM; AVERSION THERAPY; AWARENESS; BIOACCUMULATION; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE BEHAVIORAL THERAPY; COUNSELING; DNA DAMAGE; ELECTRONIC CIGARETTE; ETHNICITY; GENE MUTATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; HYPNOSIS; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG CIRCULATION; NATIONAL HEALTH SERVICE; PERIPHERAL VASCULAR DISEASE; REVIEW; SELF HELP; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW; TH2 CELL; TOBACCO DEPENDENCE; UNITED STATES; CIGARETTE SMOKING; PREVALENCE;

UNITED STATES;

NICOTIANA TABACUM;

CIGARETTE SMOKING; HUMANS; NICOTINE; PREVALENCE; TOBACCO USE CESSATION; UNITED STATES;

EID: 85030471633     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph14101147     Document Type: Review

References (56)

1. Hu, S.S.; Neff, L.; Agaku, I.T.; Cox, S.; Day, H.R.; Holder-Hayes, E.; King, B.A. Tobacco product use among adults-United States, 2013-2014. Morb. Mortal. Wkly. Rep. 2016, 65, 685-691.
2. Benowitz, N.L.; Hukkanen, J.; Jacob, P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 2009, 192, 29-60.
3. Jamal, A.; King, B.A.; Neff, L.J.; Whitmill, J.; Babb, S.D.; Graffunder, C.M. Current cigarette smoking among adults-United States, 2005-2015. Morb. Mortal. Wkly. Rep. 2016, 65, 1205-1211.
4. World Health Organization. Monitoring Tobacco Use and Prevention Policies; World Health Organization:Geneva, Switzerland, 2017.
5. World Health Organization. WHO Report on the Global Tobacco Epidemic: Raising Taxes on Tobacco; World Health Organization: Geneva, Switzerland, 2015; pp. 52-53.
6. Cooperman, N.A.; Bernstein, S.L.; Williams, J.M. Determining smoking cessation related information, motivation, and behavioral skills among opiate dependent smokers in methadone treatment. Subst. Use Misuse 2016, 50, 566-581.
7. Santhosh, L.; Meriwether, M.; Saucedo, C.; Reyes, R.; Cheng, C.; Clark, B.; Tipperman, D.; Schroeder, S. A. From the sidelines to the frontline: How the substance abuse and mental health services administration embraced smoking cessation. Am. J. Public Health 2014, 104, 796-802, doi:10.2105/AJPH.2013.301852.
8. U.S. Department of Health and Human Services. Preventing Tobacco Use among Youth and Young Adults A Report of the Surgeon General Executive Summary; Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2012.
9. U.S. Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress:A Report of the Surgeon General; Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2014; pp. 1-36;
10. Singh, T.; Arrazola, R.A.; Neff, L.J.; Kennedy, S.M.; Holder-Hayes, E.; Jones, C.D. Tobacco use among middle and high school students-United States, 2011-2015. MMWR Morb. Mortal. Wkly. Rep. 2015, 65, 361-367.
11. Brown, J.; Beard, E.; Kotz, D.; Michie, S.; West, R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: A cross-sectional population study. Addiction 2014, 109, 1531-1540.
12. D’Ruiz, C.D.; Graff, D.W.; Yan, X.S. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes. BMC Public Health 2015, 15, 991.
13. Callahan-Lyon, P. Electronic cigarettes: Human health effects. Tob. Control 2014, doi:10.1136/tobaccocontrol-2013-051470.
14. Rahman, M.A.; Hann, N.; Wilson, A.; Worrall-Carter, L. Electronic cigarettes: Patterns of use, health effects, use in smoking cessation and regulatory issues. Tob. Induc. Dis. 2014, 12, 21.
15. U.S. Department of Health and Human Services. E-Cigarette Use among Youth and Young Adults: A Report of the Surgeon General; Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2016.
16. Centers for Disease Control and Prevention Office of Smoking and Health. E-Cigarette Information; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2015;
17. Protano, C.; Di Milia, L.M.; Orsi, G.B.; Vitali, M. Electronic cigarette: A threat or an opportunity for public health? State of the art and future perspectives. Clin. Ter. 2015, 166, 32-37.
18. Nicotine|C10H14N2-PubChem. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/89594#section=Top (accessed on 21 September 2017).
19. Burns, D.M. Nicotine addiction. In Harrison’s Principles of Internal Medicine, 19th ed.; Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J.L., Loscalzo, J., Eds.; McGraw-Hill Education: New York, NY, USA, 2015.
20. Doering, P.L.; Li, R.M. Substance-related disorders II: Alcohol, nicotine, and caffeine. In Pharmacotherapy:A Pathophysiologic Approach, 9th ed.; DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., Eds.; The McGraw-Hill Companies: New York, NY, USA, 2014.
21. Soghoian, S. Nicotine. In Goldfrank’s Toxicologic Emergencies, 10th ed.; Hoffman, R.S., Howland, M.A., Lewin, N.A., Nelson, L.S., Goldfrank, L.R., Eds.; McGraw-Hill Education: New York, NY, USA, 2015.
22. O’Brien, C.P. Drug addiction. In Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 12th ed.; Brunton, L.L., Chabner, B.A., Knollmann, B.C., Eds.; McGraw-Hill Education: New York, NY, USA, 2011.
23. Nicotine 2D Structure. Available online: https://pubchem.ncbi.nlm.nih.gov/image/imagefly.cgi?cid=89594&width=500&height=500 (accessed on 21 September 2017).
24. Benowitz, N.L.; Brunetta, P.G. Smoking Hazards and Cessation, 5th ed.; Elsevier Inc.: Amsterdam, The Netherlands, 2010.
25. United States Department of Health and Human Services. How Tobacco Smoke Causes Disease: A Report of the Surgeon General; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, USA, 2010.
26. Rakel, R.E.; Houston, T. Nicotine Addiction. In Textbook of Family Medicine; Rakel, R.E., Rakel, D.P., Eds.; Elsevier Health Sciences: Philadelphia, PA, USA, 2011; pp. 1105-1122.
27. Global Initiative for Chronic Obsructive Lung Disease (GOLD) 2017. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obsructive Lung Disease., 2017. Avaliable online: http://goldcopd.org/gold-2017-globalstrategy-diagnosis-management-prevention-copd/ (accessed on 10 January 2017)
28. Harris, K.K.; Zopey, M.; Friedman, T.C. Metabolic effects of smoking cessation. Nat. Rev. Endocrinol. 2016, doi:10.1038/nrendo.2016.32.
29. Fiore, M.C.; Jaén, C.R.; Baker, T.B.; Bailey, W.C.; Benowitz, N.L.; Curry, S.J.; Dorfman, S.F.; Froelicher, E.S.; Goldstein, M.G.; Healton, C.G.; et al. Treating Tobacco Use and Dependence: 2008 Update; Clinical Practice Guideline; US Department of Health and Human Services: Rockville, MD, USA, 2008.
30. Fiore, M.C.; Baker, T.B. Treating smokers in the health care setting. N. Engl. J. Med. 2011, 365, 1222-1231.
31. Niaura, R. Nonpharmacologic therapy for smoking cessation: Characteristics and efficacy of current approaches. Am. J. Med. 2008, 121, S11-S19.
32. Twyman, L.; Bonevski, B.; Paul, C.; Bryant, J. Perceived barriers to smoking cessation in selected vulnerable groups: A systematic review of the qualitative and quantitative literature. BMJ Open 2014, 4, e006414.
33. White, A.R.; Rampes, H.; Liu, J.P.; Stead, L.F.; Campbell, J. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst. Rev. 2011, doi:10.1002/14651858.cd000009.pub3.
34. Hajek, P.; Stead, L.F. Aversive smoking for smoking cessation. Cochrane Database Syst. Rev. 2004, doi:10.1002/14651858.CD000546.pub2.
35. Barnes, J.; Dong, C.Y.; McRobbie, H.; Walker, N.; Mehta, M.; Stead, L.F. Hypnotherapy for smoking cessation. Cochrane Database Syst. Rev. 2010, doi:10.1002/14651858.cd001008.pub2.
36. Stead, L.F.; Lancaster, T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. 2012, doi:10.1002/14651858.cd008286.pub2.
37. Nides, M. Update on pharmacologic options for smoking cessation treatment. Am. J. Med. 2008, 121, S20-S31.
38. Hays, J.T.; McFadden, D.D.; Ebbert, J.O. Pharmacologic agents for tobacco dependence treatment: 2011 update. Curr. Atheroscler. Rep. 2012, 14, 85-92.
39. Eisenberg, M.J.; Filion, K.B.; Yavin, D.; Belisle, P.; Mottillo, S.; Joseph, L.; Gervais, A.; O’Loughlin, J.; Paradis, G.; Rinfret, S.; et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. CMAJ 2008, 179, 135-144.
40. Stead, L.; Perera, R.; Bullen, C.; Mant, D.; Cahill, K.; Lancaster, T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2012, doi:10.1002/14651858.CD000146.pub4.
41. Hajek, P.; West, R.; Foulds, J.; Nilsson, F.; Burrows, S.; Meadow, A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. 1999, 159, 2033-2038.
42. Hays, J.T.; Ebbert, J.O. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010, 70, 2357-2372.
43. Dempsey, D.A.; Benowitz, N.L. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 2001, 24, 277-322.
44. Hughes, J.; Stead, L.; Cahill, K.; Lancaster, T. Antidepressants for smoking cessation. Cochrane Libr. 2014, doi:10.1002/14651858.CD000031.pub3.
45. U.S. Food and Drug Administration. Information for Healthcare Professionals: Varenicline (Marketed as Chantix) and Bupropion (Marketed as Zyban, Wellbutrin, and GEnerics). Available online:https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/Dru gSafetyInformationforHeathcareProfessionals/ucm169986.htm (accessed on 5 July 2017).
46. GlaxoSmithKline. Zyban (Bupropion Hydrochloride) [Prescribing Information]; Research Triangle Park:Durham, NC, USA, 2017.
47. Tonstad, S.; Farsang, C.; Klaene, G.; Lewis, K.; Manolis, A.; Perruchoud, A.P.; Silagy, C.; van Spiegel, P.I.; Astbury, C.; Hider, A.; et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease:A multicentre, randomised study. Eur. Heart J. 2003, 24, 946-955.
48. Cahill, K.; Lindson-Hawley, N.; Thomas, K.; Fanshawe, T.; Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2016, doi:10.1002/14651858.CD006103.pub7.
49. U.S. Food and Drug Administration. FDA Drug Safety Communication: Chantix (Varenicline) Drug Label Now Contains Updated Efficacy and Safety Information. Available online: https://www.fda.gov/Drugs/DrugSafety/ucm264436.htm (accessed on 5 July 2017).
50. U.S. Food and Drug Administration. FDA Drug Safety Communication: Chantix (Varenicline) May Increase the Risk of Certain Cardiovascular Adverse Events in Patients with Cardiovascular Disease. Available online: https://www.fda.gov/Drugs/DrugSafety/ucm259161.htm (accessed on 5 July 2017).
51. Pfizer Inc. Chantix (Varenicline) [Prescribing Information].; Pfizer Inc.: New York, NY, USA, 2016.
52. Gourlay, S.; Stead, L.; Benowitz, N. Clonidine for smoking cessation. Cochrane Database Syst. Rev. 2004, cd000058.
53. Hughes, J.R.; Stead, L.F.; Lancaster, T. Nortriptyline for smoking cessation: A review. Nicotine Tob. Res. 2005, 7, 491-499.
54. Truven Health Analytics. Red Book Online® System (Electronic Version); Truven Health Analytics: Greenwood Village, CO, USA, 2016.
55. U.S. Department of Health and Human Services. Healthy People 2020: Tobacco Use. Available online:https://www.healthypeople.gov/2020/topics-objectives/topic/tobacco-use (accessed on 5 July 2017).
56. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-2014.; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health:Atlanta, GA, USA, 2014.